A Single-center, Phase II Clinical Trial Evaluating the Efficacy of Sacituzumab Tirumotecan in Combination With Tagitanlimab as Neoadjuvant Therapy for PD-L1-positive, Resectable Stage II to IIIB Non-small Cell Lung Cancer (NSCLC)

Name: A Single-center, Phase II Clinical Trial Evaluating the Efficacy of Sacituzumab Tirumotecan in Combination With Tagitanlimab as Neoadjuvant Therapy for PD-L1-positive, Resectable Stage II to IIIB Non-small Cell Lung Cancer (NSCLC)
License: Public Domain

Henan Cancer Hospital

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

resectable stage ii-iiib nsclc

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 127587
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.